mouse myccap cells  (ATCC)

Journal: Nature Communications

Article Title: Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS

doi: 10.1038/s41467-026-68913-3

Figure Lengend Snippet: Differential cell toxicity following treatment with HYDRAC or P-sHR. Representative dose-response plots of PC3 ( a ), A549 ( b ), or MycCaP ( c ) cells following 72 h treatment with viability normalized to vehicle-treated control from n = 3 technical replicates. d Summary IC 50 values in PC3 and A549 cells following treatment with indicated polymers averaged from n = 3 independent biological experiments with > 2 different batch formulations. e Annexin V/PI staining of PC3 cells treated for 24 h with HYDRAC analyzed by flow cytometry and split into late (Annexin V-FITC + /PI + ) and early (Annexin V-FITC + /PI + ) stage apoptosis. The DMSO group was incubated with 10% DMSO as a positive control. n = 3 independent samples per group. Experiment repeated with similar results. f Representative dose-response curves of PC3 cells treated for 72 h with HYDRACs consisting of different targeting ligand to degron ratios with viability normalized to vehicle-treated controls. g PC3 (solid) or PC12 (dashed) cells were treated with HYDRAC for 72 h and cell viability was normalized to vehicle treatment. IC 50 values listed. h A549 cells were incubated with a single treatment of 10 or 20 μM of the indicated polymer formulations at day 0, and cell counts were normalized to the initial seeding amount monitored over 2 weeks. Data depict mean ± s.d. P -values determined by one-way ANOVA in d, e . One representative dose-response or proliferation curve from n = 3 independent experiments is shown in ( f), ( g ), and ( h ). * P < 0.05, ** P < 0.01, ns: not significant.

Article Snippet: PC-3, PC-12, A549, 293T, and HCT116 cells were obtained from ATCC; Mouse MycCaP cells were the kind gift of Charles Sawyers (Memorial Sloan-Kettering Cancer Centre); HCT116 KEAP1 KO cells were obtained from Abcam (ab286484); 293 T VHL KO cells were obtained from Creative Biogene (CSC-RT2714).

Techniques: Control, Staining, Flow Cytometry, Incubation, Positive Control, Polymer

Journal: Cell reports

Article Title: BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways

doi: 10.1016/j.celrep.2025.115779

Figure Lengend Snippet: (A) Schema showing the experimental design for venetoclax and ENZA combination treatment on castration-sensitive mouse GEM (genetically engineered mouse) tumor-derived cell CSPC (MYCCaP) in immunogenic FVB mice. Schema created with BioRender.com . (B) Growth curve of subcutaneously implanted MYCCaP cells ( n = 8 each group) treated with vehicle control (% DMSO, 30% PEG300), ENZA (30 mg/kg body weight), venetoclax (100 mg/kg body weight), and combination (ENZA, 30 mg/kg; venetoclax, 100 mg/kg). Drugs were delivered to the mice through oral gavage, once each day, until the end of the experiment. Error bar, SD; unpaired t test. (C) Growth curve of individual mouse tumor growth during the combination-treatment study. (D) Survival curve of the mice. Error bar, SD; log rank Mantel-Cox test. Statistical values are calculated by GraphPad Prism. (E) Representative histopathological (scale bar, 500 μm) and immunohistochemical (scale bar, 100 μM) staining of AR and KI67 in the MYCCaP mouse tumors. (F) The graph represents the number of ki67-positive cells/high power field (hpf) in the mouse tumors of each group. 10 hpf of each tumor sections were selected. Error bar, SD; unpaired t test. (G) Western blot showing the expression of indicated proteins in MYCCaP tumors either treated with vehicle or ENZA. Each lane represents an individual mouse tumor. (H) LNCaP cells were transiently transfected with BCL2 siRNA or scrambled/control (Scr) siRNA. 48 h post transfection, cells (1 × 10 4 /well) were cultured in a low-adherence plate for anchorage-independent tumorsphere-formation assay in tumorsphere medium supplemented with 1 nM R1881 alone or in combination with 10 μM ENZA (ENZ) for another 2 weeks. Equivalent volume of DMSO was used as placebo treatment. The representative images (50× magnification) showing the changes of tumorsphere formation in response to BCL2 knockdown and ENZ treatment. Scale bar, 500 μm. (I) WB showing the expression of indicated proteins in LNCaP-abl cells treated with 0.1 and 1 μM MK2206 for 24 h under ADT (CSS). n = 3 biological replicates. (J) qPCR showing the expression of BCL2 mRNA expression in LNCaP-Abl cells when treated with 0.1 and 1 μM MK2206 (Akt inhibitor) for 24 h under ADT (CSS). n = 3 biological replicates. Error bar, SD. (K) Schema of the regulation of BCl2 expression in castration-resistant PTEN-null PC cells. (L) Bar graph showing the cell growth of LNCaP-Abl cells when treated with venetoclax (7.7 μM), MK2206 (1 μM), or in combination for 7 days. Cell growth was measured by MTT. Error bar, SD; unpaired t test. Data represent eight biological replicates.

Article Snippet: Human prostate cancer cells LNCaP, 22RV1, DU145, PC3, VCaP, human breast carcinoma cells MDA-MB-231 and castration sensitive mice prostate cancer cell MYCCaP were obtained from ATCC (Manassas, VA).

Techniques: Derivative Assay, Control, Immunohistochemical staining, Staining, Western Blot, Expressing, Transfection, Cell Culture, Tube Formation Assay, Knockdown